T-DM1 can counteract the invasion-promoting effects of Heregulin on HER-2-positive breast cancer cells [30, 31], potentially providing a theoretical basis for the radiosensitizing effect of T-DM1 combined with radiotherapy in HER-2-positive breast cancer (Fig. 1). Here, ERBB2 is linked to breast carcinoma.